Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tenax Therapeutics Inc.

www.tenaxthera.com

Latest From Tenax Therapeutics Inc.

ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS

Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.

Rare Diseases Approvals

Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda

First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.

Financing StartUps and SMEs

Pipeline Watch: Evolocumab, Roxadustat And SB-204, Top-line Results

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

PIPELINE WATCH: A Strong Analgesic Meets Primary Endpoint, But An RNAi Therapeutic Disappoints

Pipeline Watch has been updated to bring greater depth and detail to a product’s progress through the R&D pipeline, and is now a snapshot of late-stage, Phase II and III clinical trial events for drugs being evaluated by the pharma and biotech industries that is now available to view.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cardiovascular
  • Respiratory, Pulmonary
  • Alias(es)
  • Oxygen Biotherapeutics Inc.
  • Synthetic Blood International Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tenax Therapeutics Inc.
  • Senior Management
  • Anthony A DiTonno, CEO
    Michael B Jebsen, Pres. & CFO
    Doug Randall, VP, Commercial & Bus. Operations
  • Contact Info
  • Tenax Therapeutics Inc.
    Phone: (919) 855-2100
    1 Copley Pkwy., Ste. 490
    Morrisville, NC 27560
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register